Xeris Biopharma (XERS) Fundamental Analysis: Revenue, Earnings & Valuation

4.89 / 10

Netural

Fundamental analysis yields a 4.9/10 score, indicating fair health. Strong points include high inventory turnover, low cost‑of‑sales ratio, and robust YoY revenue growth (~44%). Weaknesses are low interest coverage (1.02) and a high long‑term debt‑to‑working‑capital ratio, suggesting leverage risk.

Analysis Checks(9/10)

Revenue-MV

Value-0.67

Score3/3

Weight29.72%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value43.72

Score2/3

Weight0.41%

1M Return0.13%

Inventory turnover ratio

Value0.73

Score3/3

Weight-2.92%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value29.63

Score3/3

Weight5.52%

1M Return1.67%

PB-ROE

Value2.09

Score2/3

Weight27.72%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value1.99

Score1/3

Weight-2.00%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value1.02

Score2/3

Weight-3.45%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value43.72

Score2/3

Weight0.17%

1M Return0.05%

Cost of sales ratio (%)

Value14.59

Score3/3

Weight0.86%

1M Return0.26%

Asset-MV

Value-0.55

Score2/3

Weight43.96%

1M Return11.12%

Is XERS fundamentally strong?

XERS scores 4.89/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 0.19% net margin, 1879.94 P/E ratio, 76.08 P/B ratio, and 100.00% earnings growth, these metrics solidify its Netural investment rating.